Sudeep Pharma Ltd IPO

Company Overview:

Sudeep Pharma Ltd, incorporated in 1989, is a leading manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients, supplying to 100+ countries.The company operates six state-of-the-art manufacturing facilities with a combined capacity of 50,000 MT, producing a wide range of mineral-based ingredients such as calcium, iron, magnesium, zinc, potassium, and sodium.

With over 200 products across pharma, food, and nutrition segments and strong in-house R&D, Sudeep Pharma is positioned as a global player in the high-entry-barrier ingredients market.

Business Segments:

1. Pharmaceutical, Food & Nutrition Business

2. Specialty Ingredients Business

3. Triturates

Key Financial Insights:

• Revenue growing steadily: ₹429 Cr → ₹459 Cr → ₹502 Cr.

• Profits rising sharply: ₹62 Cr → ₹133 Cr → ₹139 Cr, showing strong margin improvement.

• Debt manageable but higher in FY25: ₹135 Cr vs ₹82 Cr in FY23.

• Valuation is premium: PE 48.29 vs sector PE 24.84; P/B 9.83 vs sector 2.77.

  
  

Key Strengths:

• Strong R&D and innovation capabilities backed by in-house labs and pilot facilities.

• Experienced management with deep domain expertise.

• Advanced, globally certified manufacturing facilities with scalable capacity.

• Long-standing relationships with global blue-chip and Fortune 500 clients.

• Market leadership in mineral-based ingredients with a diversified product portfolio.

• Participation in a high-entry-barrier industry, ensuring competitive advantage.

Key Risks:

• Few customers contribute major revenue – concentration risk.

• 50%+ revenue comes from one segment, limiting diversification.

• Quality lapses or audit failures could lead to loss of orders and reputational damage.

• Heavy geographical concentration in Gujarat, creating exposure to regional disruptions.

• Delays or failures in new product development may hinder growth.

Sudeep Pharma IPO – Key Details

• IPO Dates: 21 – 25 November 2025

• Price Band: ₹563 to ₹593 per share

• Lot Size: 25 shares

• Total Issue Size: ₹895 Cr

• Fresh Issue: ₹95 Cr

• Offer for Sale: ₹800 Cr

• Retail Quota: 35%

• GMP (Informational Only): 12%

  
  

Allotment Link

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matters published here are purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. Any reader making decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in the stock market is subject to unpredictable market-related risks. The author has no plans to invest in this offer and also the author does not recommend investing in any offer published on this website.